

Zinc Supplementation in Treatment of Children With Urinary Tract Infection

Parsa Yousefichaijan,¹ Mahdyieh Naziri,² Hassan Taherahmadi,¹ Manijeh Kahbazi,¹ Aram Tabaei¹

¹Department of Pediatric Nephrology, Amirkabir Hospital, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran

²Department of Basic Sciences, Arak University of Medical Sciences, Arak, Iran

Keywords. child, urinary tract infection, zinc supplement

Introduction. Urinary tract infection (UTI) is very common in children. Precocious diagnosis and appropriate treatment are important because of the permanent disease complications. Zinc increases the response to treatment in many infections. In this study, we explored the effect of zinc in treating UTI.

Materials and Methods. Two hundred children with UTI were divided into 2 groups of 100 who were comparable in terms of age, sex, urine laboratory profiles, and clinical signs and symptoms. The control group received a standard treatment protocol for UTI and the intervention group received oral zinc sulfate syrup plus routine treatment of UTI.

Results. A faster recovery was observed in the patients receiving zinc, but abdominal pain was exacerbated by zinc and lasted longer. Three months after the treatment, there was no significant difference between the two groups in the time of fever stop and negative urine culture.

Conclusions. In children with UTI, zinc supplementation has a positive effect in ameliorating severe dysuria and urinary frequency while the use of this medication is not recommended in the presence of abdominal pain.

IJKD 2016;10:213-6
www.ijkd.org

INTRODUCTION

Urinary tract infection (UTI) is the most common disease of the urinary tract system and the 2nd prevalent infection in children after viral flu.¹ Unlike in adults, UTI in children does not have characteristic symptoms and sometimes occurs with atypical presentations such as weight loss, growth failure and anorexia, jaundice, and fever of unknown origin.²⁻⁷ Precocious diagnosis and appropriate treatment are important because of the disease complications, including precocious complications such as sepsis and bacteremia, and late complications such as hypertension, chronic kidney failure, and nephropathy reflux.⁸⁻¹²

Zinc is the 2nd most abundant mineral in the body and its existence is important to synthesis and metabolism of proteins and nucleic acids, as well as the stability of cell membranes.¹³ Zinc acts as a

cofactor for over 200 enzymes, and it is essential for many metabolic functions of a cell. In general, physiological functions are dynamically linked to zinc, including growth, cell division, puberty, reproduction, and regulation of host's immune system. The immune system function is impaired even in cases of moderate zinc deficiency.^{14,15} Severe zinc deficiency reduces immune system function. Zinc is one of the body's protective mechanisms against rare diseases. This mineral is necessary for the development and activity of T lymphocytes. Zinc deficiency causes a reduction in cellular immunity and duration of some diseases such as diarrhea. Zinc plays a role in the production of interferon- γ , interleukin-2, and tumor necrosis factor- α .^{16,17}

Unfortunately, to our knowledge, there is no study on the effectiveness of zinc in treating UTI

in children. Appropriate treatment is crucial in a way that it can prevent permanent kidney damage (kidney scar). Therefore the use of medicinal and nonmedicinal substances which can help us to prevent kidney damage is necessary and useful. Given that zinc is a nutrient that plays a role in the regulation and improvement of the immune system, this study aimed to evaluate the use of zinc for boosting the immune system function, and thus its effectiveness in the treatment of pyelonephritis.

MATERIALS AND METHODS

This clinical trial was conducted on the children with UTI who were hospitalized in Amirkabir Hospital. The study protocol was approved by the Ethics Committee of Arak University of Medical Sciences. Indications for hospitalization included absence of a previous UTI history, dehydration (moderate to severe), inability to drink fluids and medications (oral drug intolerance), vomiting, and suspected blood infection and UTI at the same time.¹⁸ The inclusion criteria was existence of UTI, an age of 3 to 12 years old, and indications for hospitalization to receive intravenous medication. Patients who were not willing to participate or to take medication were excluded from the study. Other exclusion criteria were a diagnosis of renal scarring based on the results of dimercaptosuccinic acid scan; history of any form of UTI; vesicoureteral reflux, symptoms of renal abscess, renal and urinary tract calculus, urinary tract obstruction, emphysematous pyelonephritis, renal hypoplasia, ectopic kidney, and any unilateral or bilateral renal anomaly based on ultrasonography, computed tomography scan, and voiding cystourethrography findings; neurogenic bladder; history of voiding dysfunctions; anatomical problems of the genitalia such as labial adhesion, trauma, surgery, and congenital anomalies; history of diabetes mellitus, immunodeficiency, and organ transplantation; severe sepsis and bacteremia; and severe dehydration.

Two hundred eligible children were enrolled in the study after explaining the study to their parents and obtaining written consent. Using random assignment, they were divided into 2 experimental and control groups (each comprising of 100 children). On admission, all of the children received intravenous ceftriaxone (Jabir Ibn Hayyan, Tehrna, Iran) at a dose of 50 mg/kg/d to 75 mg/kg/day, and the treatment was continued after

discharge using cefixime suspension (Farabi, Tehran, Iran). The total duration of treatment was 14 days. In the study group, in addition to the standard treatment, all of the patients received zinc syrup (1 mg/kg/d) for 14 days (Razak, Tehran, Iran).

Data were collected during hospitalization and after discharge on the time of becoming fever free, dysuria, abdominal pain, urinary frequency, time of negative urine culture, dribbling, and the time of improving urinary incontinence. The method of measuring dysuria, abdominal pain, and urinary frequency was that children reported their parents each of the above symptoms during urination at every turn and during the treatment period, based on which the rate of dysuria reduction, urinary frequency, and abdominal pain was calculated.

Laboratory tests included complete blood count; measurement of serum levels of urea, creatinine, sodium, and potassium; and urinalysis and urine culture, 48 hours and 7 to 10 days after the start of the treatment, and then every month for 3 months.

Comparisons between the two groups were performed using the chi-square test, Fisher exact test, and independent *t* test.

RESULTS

There was no significant difference between the study (zinc) and control groups in terms of the time of fever stop or the frequency of negative urine culture (none of the measurements), urinary incontinence, and dribbling (Tables 1 and 2). In the zinc group, the number of days with dysuria, urinary frequency, and urgency were significantly less, and the recovery time was reported faster (Table 2). Abdominal pain and dysuria, however,

Table 1. Positive Urine Culture for Microorganisms in Children With Urinary Tract Infection

Urine Culture Time	Positive Urine Culture		P
	Zinc Group (n = 100)	Control Group (n = 100)	
48 hours after starting treatment	7	11	.23
7 to 10 days after starting treatment	3	6	.25
1 month after starting treatment	1	2	.56
2 months after starting treatment	0	1	.32
3 months after starting treatment	0	0	> .99

Table 2. Symptoms in Children With Urinary Tract Infection

Symptoms	Patients With Symptom (%)		P
	Zinc Group	Control Group	
Days with fever			
1	37 (50.0)	37 (50.0)	
2	28 (52.8)	25 (47.2)	
3	27 (51.9)	25 (48.1)	
4	1 (33.3)	2 (66.7)	.92
Days with dysuria			
1	29 (64.4)	16 (35.6)	
2	18 (42.9)	24 (57.1)	
3	12 (30.0)	28 (70.0)	
4	0 (0.0)	1 (100.0)	.01
Days with frequency			
1	35 (79.5)	9 (20.5)	
2	21 (52.5)	19 (47.5)	
3	14 (48.3)	15 (51.7)	
4	0 (0.0)	3 (100.0)	
5	0 (0.0)	1 (100.0)	.004
Days with incontinuity			
1	36 (63.2)	21 (36.8)	
2	21 (48.8)	22 (51.2)	
3	12 (46.2)	14 (53.8)	
4	0	1 (100)	
5	0	2 (100)	.16
Days with dribbling			
1	27 (58.7)	19 (41.3)	
2	20 (48.8)	21 (51.2)	
3	11 (52.4)	10 (47.6)	.65
Days with urgency			
1	36 (60.0)	24 (40.0)	
2	23 (48.9)	24 (51.1)	
3	15 (55.6)	12 (44.4)	
4	0	2 (100)	.03

were longer in the zinc group, which was likely due to the abdominal pain after taking zinc (Table 2).

DISCUSSION

The aim of this study was to determine the effect of zinc on treatment of UTI in children. The two groups were comparable in terms of age, sex, urine laboratory characteristics, and clinical condition and symptoms such as fever, dysuria, and urinary frequency. The results showed that in UTI with severe dysuria and urinary frequency, zinc is an effective medication in reducing the symptoms, but it was associated with more abdominal pain.

Zinc deficiency with an immunodeficiency and increase in creating background of infections are common in developing countries such as Iran, in which children are susceptible to viral and bacterial infections. In these areas, the use of zinc as a

supplement or treatment can significantly improve the immune system and help to deal with infections.¹⁹ Previous studies have shown that the use of zinc can help to improve symptoms in patients with lower respiratory tract infections.^{20,21} Zinc spray has also been used successfully in the treatment of upper respiratory disease.²¹ Other studies suggest that zinc sulfate is useful in the prevention of diarrhea and pneumonia.²²⁻²⁴ It has been shown that the use of zinc for 14 days improves the immune response to *Shigella* infections in developing countries where malnutrition is common.^{25,26} Zinc also reduces the burden of disease in children under 5 years of age and increases the body resistance to infectious diseases such as influenza.^{27,28}

According to the results of previous studies, there is no organized report on the effects of zinc sulfate in the treatment of UTI, and given the fact that UTI is a major risk factor for kidney injury in children that leads to many complications, the use of suitable therapeutic methods which facilitate more rapid recovery of the patients and prevent other complications is highly recommended. Our results showed that zinc could be effective for reducing dysuria and frequent urination, but not other symptoms; in addition, it increased abdominal pain as a side effect.

As mentioned above, zinc is useful in improving frequent urination and dysuria, but it may increase abdominal pain; thus, we conclude that zinc as an adjunct medication can be used to treat the symptoms in children who suffer from dysuria and frequent urination; however, its use is not recommended for children who experience abdominal pain.

One challenge of the study was nonadherence of the parents to the treatment and follow-up protocol. There was also concerns about reliability of self-report and expression of symptoms by the children, in order to make a proper evaluation of the treatment process. The results might have been affected by the patterns of bringing the children for hospitalization by the parents, early hospital discharge, and oral zinc intolerance by children.

CONCLUSIONS

According to the obtained results, zinc can be used for clinical improvement in cases of severe dysuria and frequent urination among children with UTI. More investigation with larger samples are required to confirm these findings.

ACKNOWLEDGEMENTS

The article was retrieved from the thesis project of Aram Tabaei. We hereby express our sincere appreciation to the staff of Amirkabir Research Center.

CONFLICT OF INTEREST

None declared.

REFERENCES

1. Yousefichaijan P, Dorreh F, Gazerani N. Effect of ablation the genital area on result of urine culturing among 3-12 years old girls referring to Amir Kabir hospital, Arak, Iran. *Arch Clin Infect Dis*. 2010;5:133-6.
2. Kennedy KM, Glynn LG, Dineen B. A survey of the management of urinary tract infection in children in primary care and comparison with NICE guidelines. *BMC Fam Pract*. 2010;11:6.
3. Grossman Z, Miron D. Imaging and follow-up of children with first febrile urinary tract infection (UTI). *Harefuah*. 2009;148:716-720,732.
4. Merguerian PA, Sverrisson EF, Herz DB, Mcquiston LT. Urinary tract infection in children: recommendations for antibiotic prophylaxis and evaluation. An evidence-based approach. *Curr Urol Rep*. 2010;11:98-108.
5. Yousefichaijan P, Sharafkhan M. A Comparison between Bacterial Resistance to Common Antibiotics in Breast-Fed and Bottle-Fed Female Infants with Urinary Tract Infection. *Arch Clin Infect Dis*. 2014;7:113-5.
6. Yousefichaijan P, Dorreh F. Urinary tract infection due to salmonella in an otherwise healthy child. *Iran J Kidney Dis*. 2014;8:155-7.
7. Yousefichaijan P, Kahbazi M, Rasti S, Rafiei M, Sharafkhan M. Vitamin E as adjuvant treatment for urinary tract infection in girls with acute pyelonephritis. *Iran J Kidney Dis*. 2015;9:97-104.
8. Taneja N, chatterjee SS, Singh M, Singh S, Sharma M. Pediatric urinary tract infection in a tertiary care center from north India. *Indian J Med Res*. 2010;131:101-5.
9. Avner ED, Harmon WE, Niavdet P. *Pediatric nephrology*. 5th ed. Philadelphia: Wolters Kluwer; 2004. p: 1007-11.
10. Tanagho EA, McAninch JW. *Smith's general urology*. 15th ed. New York: Lange Medical Books/Graw Hills;2000. p. 237-321.
11. Yousefichaijan P, Cyrus A, Dorreh F. Evaluation of additional fluid (1.5 times the maintenance) on the urinary tract infections therapy in Children. *J Ardabil Univ Med Sci*. 2008;8:321-5.
12. Yousefichaijan P, Cyrus A, Moghaddasi Z, Dorreh F, Garavand F. The frequency of recurrence of urinary tract infection (UTI) in 1-month to 12-year-old children without congenital abnormalities referred to Arak Amir Kabir Hospital. *J Zanzan Univ Med Sci Health Serv*. 2011;19:66-76.
13. Jackson EK. Diuretics. In: Brunton LL, Lazo J, Parker KL, editors. *Goodman and Gilman's the pharmacological basis of therapeutics*. 11th ed. USA: McGraw; 2005. p. 753-89.
14. Kliegman RM, Marcadante K, Jenson HB, Behrman RE. Pediatrics nutrition and nutritional disorders. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF, editors. *Nelson essentials of pediatrics*. 5th ed. Philadelphia: WB Saunders; 2006. p. 532-5.
15. Shahraz S, Ghaziani T. *A comprehensive textbook of drug information*. 3rd ed. Tehran: Teimourzadeh; 2005. p. 744-5.
16. Abrams SA. Zinc deficiency and supplementation in children and adolescents. In: Rose BD, editor. *Uptodate*. Wellesley: 2007;15(3). [CD-ROM].
17. Elder J. Nephrology In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF, editors. *Nelson textbook of pediatrics*. 18th ed. Philadelphia: WB Saunders; 2007. p. 2223-7.
18. Bird SM, Black RE, Brown KH, et al. Therapeutic effects of oral zinc in acute and persistent diarrhea in children in developing countries: pooled analysis of randomized controlled trials 1,2,3. *Am J Clin Nutr*. 2000;72:1516-22.
19. Yousefichaijan P, Moghaddasi Z, Tabaei A. Therapeutic effects of zinc supplementation in children with urinary tract infection. *Koomesh*. 2010;12:204-8.
20. Hensley CB, Davidson R. Reduction in duration of lower Respiratory tract infection by zinc gluconate in a double blind study. *Virology*. 2005;25:20-4.
21. Belongia EA, Berg R, Lin K. A randomized trial of zinc nasal spray for the treatment of upper respiratory illness. *Am J Med*. 2001;111:103-8.
22. Brooks WA, Santosham M, Naheed A, et al. Effect of weekly zinc supplementation incidence of pneumonia and diarrhea in children young eye urban, low-income population in Bangladesh: randomized controlled trial. *Lancet*. 2005;366: 999-1004.
23. Lazzerini M, Ronfani L. Oral zinc for treating diarrhea in children. *Cochrane Database Syst Rev*. 2008;16:CD005436.
24. Rahman MJ, Sarker P, Roy SK, et al. Effect of zinc supplementation as adjunct therapy on the systemic immune response in shigellosis. *Am J Clin Nutr*. 2005;81:495-502.
25. Dchoa TJ, Cleary TG. Shigella. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF, editors. *Nelson textbook of pediatrics*. 18th ed. Philadelphia: WB Saunders; 2007. p. 1191-3.
26. Larson CP, Roy SK, Khan A, Rahman AS, Qadri F. Zinc treatment to under-five children: applications to improve survival and reduce burden of disease. *J Health Popul Nutr*. 2008;26:356-65.
27. Sabri M, Houle S, Dozois CM. Roles of the extraintestinal pathogenic *Escherichia Coli* ZnuACB and Zup zinc transporters during urinary tract infection. *Infec Immun*. 2009;77:1155-1164.
28. Sandstead HH, Prasad AS. Zinc intake and resistance to H1N1 influenza. *Am J Public Health*. 2010;100:970-1.

Correspondence to:
Mahdyieh Naziri
Department of Basic Sciences, Arak University of Medical Sciences, Arak, Iran
Tel: +98 918 849 2394
E-mail: nazirimahdyieh@yahoo.com

Received November 2015
Revised February 2016
Accepted February 2016